TTI-2341

N/A

Report date: 2026/05/08 20:02:52
NME

Base Information

Drug NameTTI-2341
Drug Alias NameTTI-2341
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR T790M inhibitorsEGFR L858R inhibitorsEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1EGFR T790MEGFR L858R
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTrillium Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTrillium Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A